Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects

European Journal of Clinical Pharmacology

Volumn 59, Issue 2, 2003, Pages 111-116

  Kim, Myo Kyoung ^a   Cho, Joo Youn ^a   Lim, Hyeong Seok ^a   Hong, Kyoung Seop ^a   Chung, Jae Yong ^a   Bae, Kyun Seop ^b   Oh, Dal Seok ^a   Shin, Sang Goo ^a   Lee, Sang Hun ^c   Lee, Dong Ho ^c   Min, Bumchan ^c   Jang, In Jin ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c Purimed RandD Institute   (South Korea)

Author keywords

CYP2D6 genotype; Pharmacokinetics; Tropisetron

Indexed keywords

CYTOCHROME P450 2D6; TROPISETRON;

ALLELE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; GENE DUPLICATION; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTH KOREA;

EID: 10744229524     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0595-1     Document Type: Article

References (27)

1. Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39:533-537
2. Bertilsson L, Dahl ML, Sjoqvist F, Aberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341:63
3. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516-520
4. de Bruijn KM (1992) Tropisetron. A review of the clinical experience. Drugs 43[Suppl 3]:11-22
5. Eichelbaum M, Gross AS (1992) The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. In: Kalow W (ed) Pharmacokinetics of drug metabolism. Pergamon Press Inc., New York, pp 625-648
6. Eichelbaum M, Spannbrucker N, Dengler HJ (1979) Influence of the defective metabolism of sparteine on its pharmacokinetics. Eur J Clin Pharmacol 16:189-194
7. Fischer V, Vickers AE, Heitz F, Mahadevan S, Baldeck JP, Minery P, Tynes R (1994) The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 22:269-274
8. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, Azuma J (1999) Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 47:450-453
9. Gaedigk A, Gotschall RR, Forbes NS, Simon SD Kearns GL, Leeder JS (1999) Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9:669-682
10. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BI, Liao CL, Zhang LM (1989) Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46:198-207
11. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 90:11825-11829
12. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 gene present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459
13. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, Possinger K, Roots I, Brockmoller J (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805-2811
14. Kees F, Farber L, Bucher M, Mair G, Morike K, Grobecker H (2001) Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br J Clin Pharmacol 52:705-707
15. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50:31-34
16. Lee CR, Plosker GL, McTavish D (1993) Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 46:925-943
17. Lundqvist E, Johansson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226:327-338
18. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586
19. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38:402-408
20. Nishida Y, Fukuda T, Yamamoto I, Azuma J (2000) CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 10:567-570
21. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L (1996) Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6:441-447
22. Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L (2001) Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 57:671-675
23. Sachse C, Brockmoller J, Hildebrand M, Muller K, Roots I (1998) Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 8:181-185
24. Sohn DR, Shin SG, Park CW, Kusaka M, Chiba K, Ishizaki T (1991) Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 32:504-507
25. Suarez A, Stettler ER, Rey E, Pons G, Simonetta-Chateauneuf C, de Bruijn KM, Olive G, Lemerle J (1994) Safety, tolerability, efficacy and plasma concentrations of tropisetron after administration at five dose levels to children receiving cancer chemotherapy. Eur J Cancer 30A:1436-1441
26. Tetsu N, Shoutaro T, Naoki M, Akinori N, Tetsushi A, Hiroshi M, Akiharu F, Takeshi M (1995) Phase I study of tropisetron capsules in healthy volunteers. Clin Rep 29:1523-1559
27. Yoon YR, Cha IJ, Shon JH, Kim KA, Cha YN, Jang IJ, Park CW, Shin SG, Flockhart DA, Shin JG (2000) Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther 67:567-576